© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
December 11, 2020
Recent years have seen calls for genetic testing for all patients with breast cancer. A session at the 2020 San Antonio Breast Cancer Symposium reviewed the evidence for, and against, such testing.
Hope Rugo, MD, director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the benefits of oral paclitaxel in metastatic breast cancer.
Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer.
A spotlight poster discussion at SABCS highlighted topics in genomic testing, potentially game-changing therapies, and predictive biomarkers in HR-positive breast cancer.
December 10, 2020
Poster presentations at the San Antonio Breast Cancer Symposium demonstrated the clinical relevance and efficacy of oral paclitaxel plus encequidar in the treatment of metastatic breast cancer.
Lee Schwartzberg, MD, FACP, chief medical director of West Cancer Center and chief medical officer of OneOncology, discusses the approvals of pembrolizumab and sacituzumab govitecan for patients with triple-negative breast cancer.
During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.
December 09, 2020
Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.
City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.
A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.